| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Brentuximab vedotin |
| Brand | Adcetris® |
| Indication | Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (license extension). |
| Assessment Process | |
| Rapid review commissioned | 07/02/2018 |
| Rapid review completed | 06/03/2018 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
The HSE has approved reimbursement following confidential price negotiations, December 2022.